Compare iShares Core S&P 500 ETF (IVV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares Core S&P 500 ETF trades at $769.73 (market cap $896.34B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares Core S&P 500 ETF is far larger — about 119.2× Spyre Therapeutics Inc. Common Stock's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IVV | SYRE | |
|---|---|---|
Market Cap | $896.34B | $7.52B |
Volume | 3,965,666 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $108.92 |
52-Week Low | $634.93 | $22.18 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $781.42 with minimal daily change. Technical analysis shows a bullish trend with strong moving average support, though RSI indicates potential overbought conditions near-term. The ETF benefits from broad market exposure amid expectations of continued corporate profit growth, with S&P 500 earnings projected to rise 35% in 2026 according to 24/7 Wall Street on October 3, 2026.
Outlook remains positive given historical seasonal trends and strong institutional support, but risks include concentration in top holdings and potential profit growth deceleration. The ETF's low-cost structure and diversification provide stability, though market volatility and economic shifts could challenge near-term performance.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
